4171.TWO GeneReach Biotechnology
- Market cap
- TWD 853M
- P/E
- -
- P/B
- 1.56x
- ROE
- -3.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4171.TWO undervalued?
Graham numberThe Graham number of GeneReach Biotechnology cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GeneReach Biotechnology fundamental analysis
No fundamental analysis for GeneReach Biotechnology yet.
GeneReach Biotechnology stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco …
Full company profileGeneReach Biotechnology financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GeneReach Biotechnology annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 155M | 187M | 366M | 857M | 1.01B | 750M | 225M | 206M | 233M | 225M |
| Gross Profit | 125M | 149M | 302M | 635M | 747M | 490M | 27.6M | 118M | 161M | 172M |
| Operating Income | -21.4M | 12.8M | 114M | 345M | 481M | 278M | -191M | -136M | -86.9M | -48.7M |
| EBITDA | -23.9M | 49.6M | 136M | 397M | 541M | 343M | -122M | -36.3M | -38.9M | 37.4M |
| Net Income | -48.1M | 28.6M | 77.2M | 257M | 377M | 221M | -166M | -119M | -110M | -18.5M |
| EPS | -1.36 | 0.80 | 1.85 | 4.47 | 6.42 | 3.73 | -2.89 | -2.07 | -1.92 | -0.33 |
| Balance Sheet | ||||||||||
| Total Assets | 603M | 694M | 761M | 1.24B | 1.68B | 1.62B | 1.18B | 1.07B | 881M | 858M |
| Total Liabilities | 352M | 383M | 168M | 383M | 596M | 519M | 314M | 341M | 284M | 277M |
| Shareholders' Equity | 251M | 289M | 556M | 813M | 1.05B | 1.07B | 832M | 717M | 587M | 573M |
| Cash & Short-term Investments | 115M | 99.5M | 177M | 356M | 677M | 764M | 532M | 110M | 155M | 151M |
| Total Debt | - | - | - | 207M | 395M | 402M | 257M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -6.83M | 5.74M | -11.2M | 170M | 349M | 358M | -38.7M | -23.2M | -13.5M | 8.21M |
| Capital Expenditure | 895K | 2.31M | 13.5M | 64.9M | 15.8M | 44.9M | 27.4M | 8.47M | 11.6M | 18.1M |
| Free Cash Flow | -8.43M | 3.44M | -24.9M | 105M | 333M | 313M | -66.0M | -31.7M | -25.2M | -9.91M |
| Ratios | ||||||||||
| ROE | -19.2% | 9.9% | 13.9% | 31.6% | 35.9% | 20.7% | -20.0% | -16.6% | -18.8% | -3.2% |
| ROA | -8.0% | 4.1% | 10.1% | 20.7% | 22.4% | 13.6% | -14.1% | -11.1% | -12.5% | -2.2% |
| Net Profit Margin | -31.0% | 15.2% | 21.1% | 30.0% | 37.2% | 29.5% | -73.7% | -57.5% | -47.4% | -8.2% |
| Debt to Equity | - | - | - | 0.25x | 0.38x | 0.38x | 0.31x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GeneReach Biotechnology dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 28, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 16.0M | 0.28 | - |
| 2023 | TWD 68.9M | 1.20 | - |
| 2022 | TWD 209M | 3.52 | 94.4% |
| 2021 | TWD 144M | 2.45 | 38.1% |
| 2020 | TWD 144M | 2.50 | 55.8% |
| 2019 | TWD 144M | 3.44 | 186.1% |
| 2018 | TWD 144M | 4.03 | 502.9% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1250:1000 on Jul 28, 2023.
Who owns GeneReach Biotechnology
- Insiders 31.14%
- Institutions 0.00%
- Public & others 68.86%
- Shares outstanding 56.9M
- Free float 38.7M
GeneReach Biotechnology company profile
- Company name
- GeneReach Biotechnology
- Ticker
- 4171.TWO
- ISIN
- TW0004171004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Central Science Park, Taichung, Taiwan, 407
- Phone
- 886 4 2463 9869
- Website
- genereach.com
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ2000 Detection & Prevention System. It also provides training program; and other services comprising molecular diagnostic technical solutions and laboratory installation, OEM/ODM contract manufacturing, and research collaborations services. The company was founded in 2004 and is headquartered in Taichung, Taiwan.
GeneReach Biotechnology management
6- Mr. Zhengzhong Liu MScChairman of the Board & Head of Public Relations
- Mr. De Yu ZhongCEO & Director
- Mr. Lu Yuan LiuChief Operating Officer
- Ms. Shuyu CaoAccounting Supervisor
- Ms. Yu-Wen HuangVice President of Compliance & Production Department
- Ms. Xiu Ying ZhangTreasurer